The U.S. will propose two bills to reduce dependence on China’s pharmaceutical industry and enhance U.S. manufacturing capabilities

The US Congress is taking action to reduce the US's dependence on China in the production of APIs

On August 3, Republican Senator Marsha Blackburn and Democratic Senator Robert Menendez proposed the "Securing America's Medicine Cabinet Act of 2021" (SAM-C)

Frank Pallone, chairman of the Energy and Commerce Committee of the House of Representatives, proposed a similar bill on July 21, requiring the FDA to cooperate with universities across the country with continuous manufacturing technology experience to promote drug production

Last year, the House of Representatives passed and proposed to the Senate a similar bill to establish a national center of excellence for continuous drug manufacturing, but it has not received any support since then

Regulatory observers pointed out that the recent Senate’s proposal to reduce the pharmaceutical industry’s dependence on China through various proposed measures may take a long time and may have limited effects

According to the U.

However, according to US media reports, as the new crown epidemic continues to cause severe damage worldwide, China's role as a global factory for APIs and preparations may have been weakened

Author: Zhilin-Acorn